Novo Nordisk to buy Akero Therapeutics, picking up promising MASH drug - statnews.com
Statnews.comarrow_outwardNovo Nordisk to buy Akero Therapeutics for up to $5.2 billion
CNBCarrow_outwardNovo Nordisk to buy Akero Therapeutics, picking up promising MASH drug
STATarrow_outwardNovo to Buy Akero for Up to $5.2 Billion for Liver Disease Boost
Bloomberg.comarrow_outwardNovo Nordisk To Buy Akero Therapeutics for $4.7 Billion - The Wall Street Journal
The Wall Street Journalarrow_outwardNovo Nordisk to acquire Akero Therapeutics for up to $5.2 billion - Investing.com India
Investing.com Indiaarrow_outwardWhat’s Driving The Super Rally In Akero Shares On Thursday Morning? - Stocktwits
Stocktwitsarrow_outwardAkero Therapeutics soars on $5.2 billion acquisition deal with Novo Nordisk - MSN
MSNarrow_outwardNovo Nordisk To Acquire Akero Therapeutics; Akero Shareholders To Receive $54/Shr, CVR Of $6/Shr - Nasdaq
Nasdaqarrow_outwardNovo Nordisk to buy MASH player Akero for $4.7B upfront - Endpoints News
Endpoints Newsarrow_outwardNovo Nordisk to buy Akero Therapeutics for up to $5.2 billion - Yahoo
Yahooarrow_outwardNovo Nordisk buys Akero Therapeutics in the US - MarketScreener
MarketScreenerarrow_outwardNovo Nordisk buys Akero Therapeutics in the US - Reuters
Reutersarrow_outwardAkero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion - GlobeNewswire
GlobeNewswirearrow_outwardAkero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion - Stock Titan
Stock Titanarrow_outwardNovo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio - Yahoo Finance
Yahoo Financearrow_outwardAkero Therapeutics Inc. stock momentum explained - 2025 Retail Activity & Weekly Stock Breakout Alerts - newser.com
Newser.comarrow_outwardNovo buying Akero and its MASH hopeful for $4.7B upfront - FirstWord Pharma
FirstWord Pharmaarrow_outwardWeiss Ratings Reaffirms Sell (D-) Rating for Akero Therapeutics (NASDAQ:AKRO) - MarketBeat
MarketBeatarrow_outwardAkero to present 96-week MASH treatment data at AASLD liver meeting - Investing.com Australia
Investing.com Australiaarrow_outwardAkero Therapeutics Announces Upcoming Presentations at the 76th Annual AASLD The Liver Meeting® 2025 on Efruxifermin Research - Quiver Quantitative
Quiver Quantitativearrow_outwardAkero Therapeutics (AKRO): Breaking Down the Stock’s Valuation After Recent Moves - Sahm
Sahmarrow_outwardHow Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio - BioSpace
BioSpacearrow_outwardAfter courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks - Fierce Biotech
Fierce Biotecharrow_outwardIs Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year? - sharewise.com
Sharewise.comarrow_outwardAkero Therapeutics Settles Loan with Hercules Capital - TipRanks
TipRanksarrow_outwardAkero Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily
Investor's Business Dailyarrow_outwardAkero Therapeutics (AKRO): Evaluating Valuation After Recent Stock Volatility - simplywall.st
Simplywall.starrow_outwardAkero Therapeutics COO sells $25k in shares - Investing.com
Investing.comarrow_outwardLatham Wins Dismissal With Prejudice for Pioneering Liver-Disease Drug Company Akero Therapeutics - Latham & Watkins LLP
Latham & Watkins LLParrow_outwardAkero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating - Seeking Alpha
Seeking Alphaarrow_outwardAkero Therapeutics Stock: Explosive Growth or Overvaluation? - StocksToTrade
StocksToTradearrow_outwardEfruxifermin in Compensated Liver Cirrhosis Caused by MASH - The New England Journal of Medicine
The New England Journal of Medicinearrow_outwardAkero Therapeutics Stock Doubles on Liver Disease Drug Trial Results - Investopedia
Investopediaarrow_outward
Akero Therapeutics close
- 2025-10-09 18:50 event
- 34 sourceslanguage
- 200+ ads_click
- 3 days ago schedule